PMGC (ELAB) Competitors

NextCure (NASDAQ:NXTC) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Which has more risk & volatility, NXTC or ELAB?

NextCure has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, PMGC has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500.

Is NXTC or ELAB more profitable?

NextCure's return on equity of -70.16% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-70.16%	-58.10%
PMGC	N/A	-77.80%	-59.17%

Does the media prefer NXTC or ELAB?

In the previous week, PMGC had 3 more articles in the media than NextCure. MarketBeat recorded 7 mentions for PMGC and 4 mentions for NextCure. NextCure's average media sentiment score of 1.29 beat PMGC's score of 0.48 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PMGC	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation & earnings, NXTC or ELAB?

NextCure is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.65M	-$1.76	-0.22
PMGC	N/A	N/A	-$6.25M	-$433.87	-0.01

Do insiders & institutionals believe in NXTC or ELAB?

42.7% of NextCure shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 0.6% of PMGC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts rate NXTC or ELAB?

NextCure presently has a consensus price target of $3.50, indicating a potential upside of 786.08%. Given NextCure's stronger consensus rating and higher probable upside, equities research analysts plainly believe NextCure is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
PMGC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NextCure beats PMGC on 10 of the 13 factors compared between the two stocks.